Federal Legislation Support, Philanthropic Activities, and Patent Challenges - Research Report on Mylan, Abbott, Actavis,

Federal Legislation Support, Philanthropic Activities, and Patent Challenges -
 Research Report on Mylan, Abbott, Actavis, AbbVie, and Agilent Technologies

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 19, 2013

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Mylan Inc.
(NASDAQ: MYL), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT),
AbbVie Inc. (NYSE: ABBV), and Agilent Technologies Inc. (NYSE: A). Today's
readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Mylan Inc. Research Report

On November 14, 2013, Mylan Inc. (Mylan) reported that it commends The School
Access to Emergency Epinephrine Act (H.R. 2094) signed by the President Barack
Obama on November 13, 2013, which is a federal legislation aimed at protecting
people with potentially life-threatening allergies. The Company reported that
the federal legislation encourages states to adopt laws allowing schools to
maintain a supply of "stock" or undesignated epinephrine, the only first-line
treatment for life-threatening allergic reactions (anaphylaxis). The Company
informed that since its launch in August 2012, Mylan has offered the program
by providing schools, upon qualification, with up to four free EpiPen
(epinephrine) or EpiPen Jr. (epinephrine) Auto-Injectors so they are available
in the event a person experiences anaphylaxis in the school setting. Heather
Bresch, CEO of Mylan, said, "Recent tragedies have reinforced that when
anaphylaxis occurs, every minute matters and immediate access to epinephrine
and emergency medical care is crucial. The new federal law is a critical step
for improving anaphylaxis preparedness in schools. We applaud those who worked
tirelessly to make this bill a reality - from Congress, government officials
and leading advocacy organizations to parents, caregivers, patients and health
care professionals." The Full Research Report on Mylan Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/5a20_MYL

--

Abbott Laboratories Research Report

On November 13, 2013, Abbott Laboratories (Abbott) announced that together
with its philanthropic foundation, the Abbott Fund, it is providing $450,000
in grants and healthcare products to deliver immediate relief to the
Philippines in the aftermath of Typhoon Haiyan. According to the Company, the
Abbott Fund is providing $350,000 in grants to CARE, Direct Relief, and the
Philippine Red Cross through the American Red Cross. Abbott further added that
it is donating up to $100,000 of critically needed products, such as
antibiotics, oral rehydration solutions and nutritionals, to its partners
Direct Relief and AmeriCares. The Full Research Report on Abbott Laboratories
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05c1_ABT

--

Actavis plc Research Report

On November 14, 2013, Actavis plc (Actavis) announced that it has filed an
Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug
Administration (FDA) seeking approval to market Testosterone Topical Solution
30mg/1.5mL. The Company reported that its ANDA product is a generic version of
Eli Lilly & Company's Axiron (Lilly), an androgen indicated for replacement
therapy in males for conditions associated with deficiency or absence of
endogenous testosterone. Actavis informed that Lilly and Acrux DDS Pty. Ltd.
filed a suit against Actavis on November 12, 2013, in the U.S. District Court
for the Southern District of Indiana seeking to prevent Actavis from
commercializing its ANDA product prior to the expiration of certain U.S.
patents. Actavis added that the lawsuit was filed under the provisions of the
Hatch-Waxman Act, resulting in a stay of final FDA approval of the Company's
ANDA for up to 30 months from the date the plaintiffs received notice of
Actavis' ANDA filing or until final resolution of the matter before the court,
whichever occurs sooner, subject to any other exclusivities. Actavis also
stated that it believes it may be a first applicant to file an ANDA for a
generic version of Axiron, and should its ANDA be approved, may be entitled to
180 days of generic market exclusivity. The Full Research Report on Actavis
plc - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/273c_ABBV

--

AbbVie Inc. Research Report

On November 14, 2013, AbbVie Inc.'s (AbbVie) stock rose 0.40%, ending the day
at $48.04. Over the previous three trading sessions, shares of AbbVie declined
1.09% compared to the S&P 500 which gained 1.06% during the same period. The
Full Research Report on AbbVie Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/4997_ACT

--

Agilent Technologies Inc. Research Report

On November 14, 2013, Agilent Technologies Inc. (Agilent Technologies)
reported its Q4 FY 2013 financial results (period ended October 31, 2013). The
Company's net revenue declined 2.8% YoY to $1.7 billion during the quarter.
Net income was $211 million or $0.63 per diluted share in Q4 FY 2013, compared
to net income of $425 million or $1.20 per diluted share in Q4 FY 2012.
Commenting on the results, Agilent Technologies CEO Bill Sullivan said, "We
finished the year with a solid quarter, building backlog and exceeding EPS
guidance despite challenges in several of our markets. This reflected our
ongoing commitment to actively manage expenses and reduce manufacturing costs
in a period of economic uncertainty. We are now well into the process of
splitting Agilent into two companies, as we announced Sept. 19. We expect to
complete the separation in early November 2014." The Full Research Report on
Agilent Technologies Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/075e_A

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)